EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Risk-stratification in frontline CLL therapy: standard of care

Eugen Tausch, Christof Schneider, Stephan Stilgenbauer

Hematology · 06.12.2024 · 2024 (1) · 457-466

DOI: 10.1182/hematology.2024000656 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology, online erschienen am 06.12.2024. Verfasst von Eugen Tausch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center Ulm and Division of CLL-Internal Medicine III, Ulm University, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Standard of Care, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of chronic lymphocytic leukemia (CLL) has been transformed over the past decade based on a better understanding of disease biology, especially regarding molecular genetic drivers and relevant signaling pathways. Agents focusing on B-cell receptor (in particular Bruton tyrosine kinase [BTK]) and apoptosis (BCL2) targets have replaced chemoimmunotherapy (CIT) as the treatment standard. BTK and BCL2 inhibitor−based therapy has consistently shown prolonged progression-free survival and in some instances even increased overall survival against CIT in frontline phase 3 trials. This improvement is particularly pronounced in high-risk CLL subgroups defined by unmutated IGHV, deletion 17p (17p−), and/or the mutation of TP53, making CIT in these subgroups essentially obsolete. Despite remarkable advances, these markers also retain a differential prognostic and predictive impact in the context of targeted therapies, mandating risk-stratification in frontline management. Furthermore, BTK- and BCL2-targeting agents differ in their adverse event profiles, requiring adjustment of treatment choice based on patient characteristics such as coexisting conditions, comedications, and delivery-of-care aspects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseStandard of CareProto-Oncogene Proteins c-bcl-2HumansRisk AssessmentImmunotherapyChromosomes, Human, Pair 17Chromosome DeletionTumor Suppressor Protein p53

Substanzen

Agammaglobulinaemia Tyrosine KinaseBTK protein, humanProto-Oncogene Proteins c-bcl-2BCL2 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Comprehensive Cancer Center Ulm and Division of CLL-Internal Medicine III, Ulm University, Germany.

Zitieren

APA

Tausch, E., Schneider, C., & Stilgenbauer, S. (2024). Risk-stratification in frontline CLL therapy: standard of care. Hematology, 2024(1), 457-466. https://doi.org/10.1182/hematology.2024000656

Vancouver

Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care. Hematology. 2024;2024(1):457-466. doi:10.1182/hematology.2024000656

BibTeX
@article{Tausch2024,
  author = {Tausch, Eugen and Schneider, Christof and Stilgenbauer, Stephan},
  title = {Risk-stratification in frontline CLL therapy: standard of care},
  journal = {Hematology},
  year = {2024},
  volume = {2024},
  number = {1},
  pages = {457--466},
  doi = {10.1182/hematology.2024000656}
}
Kostenlos starten →